norvir
Generic: ritonavir
Labeler: abbvie inc.Drug Facts
Product Profile
Brand Name
norvir
Generic Name
ritonavir
Labeler
abbvie inc.
Dosage Form
POWDER
Routes
Active Ingredients
ritonavir 100 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
0074-3399
Product ID
0074-3399_389fa9db-7528-4d2a-9518-8909d396177b
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
NDA
Application Number
NDA209512
Listing Expiration
2026-12-31
Marketing Start
2017-06-07
Pharmacologic Class
Established (EPC)
Mechanism of Action
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
00743399
Hyphenated Format
0074-3399
Supplemental Identifiers
RxCUI
UPC
UNII
NUI
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
norvir (source: ndc)
Generic Name
ritonavir (source: ndc)
Application Number
NDA209512 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 100 mg/1
Packaging
- 30 PACKET in 1 CARTON (0074-3399-30) / 1 POWDER in 1 PACKET
Packages (1)
Ingredients (1)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "389fa9db-7528-4d2a-9518-8909d396177b", "openfda": {"nui": ["N0000000246", "N0000191001", "N0000175889", "N0000190114", "N0000182137", "N0000185607", "N0000190118", "N0000185503", "N0000190113", "N0000182141", "N0000191266", "N0000185507", "N0000187064", "N0000190117"], "upc": ["0300742340304"], "unii": ["O3J8G9O825"], "rxcui": ["152971", "199249", "900575", "900577", "1926066", "1926069"], "spl_set_id": ["2849298e-de6e-47bb-8194-56e075b33fc3"], "pharm_class_epc": ["Cytochrome P450 3A Inhibitor [EPC]", "Protease Inhibitor [EPC]"], "pharm_class_moa": ["HIV Protease Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 2C19 Inducers [MoA]", "Cytochrome P450 3A Inducers [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "UDP Glucuronosyltransferases Inducers [MoA]"], "manufacturer_name": ["AbbVie Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 PACKET in 1 CARTON (0074-3399-30) / 1 POWDER in 1 PACKET", "package_ndc": "0074-3399-30", "marketing_start_date": "20170607"}], "brand_name": "Norvir", "product_id": "0074-3399_389fa9db-7528-4d2a-9518-8909d396177b", "dosage_form": "POWDER", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 3A Inhibitor [EPC]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "HIV Protease Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Protease Inhibitor [EPC]", "UDP Glucuronosyltransferases Inducers [MoA]"], "product_ndc": "0074-3399", "generic_name": "Ritonavir", "labeler_name": "AbbVie Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Norvir", "active_ingredients": [{"name": "RITONAVIR", "strength": "100 mg/1"}], "application_number": "NDA209512", "marketing_category": "NDA", "marketing_start_date": "20170607", "listing_expiration_date": "20261231"}